Harrow, Inc.

NasdaqGM:HROW Stock Report

Market Cap: US$1.2b

Harrow Management

Management criteria checks 0/4

Harrow's CEO is Mark Baum, appointed in Apr 2012, has a tenure of 12.67 years. total yearly compensation is $15.26M, comprised of 4.5% salary and 95.5% bonuses, including company stock and options. directly owns 6% of the company’s shares, worth $73.59M. The average tenure of the management team and the board of directors is 1.9 years and 2.8 years respectively.

Key information

Mark Baum

Chief executive officer

US$15.3m

Total compensation

CEO salary percentage4.5%
CEO tenure12.7yrs
CEO ownership6.0%
Management average tenure1.9yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Harrow: The Triesence Relaunch

Dec 14

Harrow: Spotlight On IHEEZO

Nov 16

Harrow's Focus - Reviving Old Drugs In A Crowded Market

Oct 02

Harrow: 3 Business Models, One Mission

Sep 10

Borrowing Cash To Burn It: The Curious Case Of Harrow

Aug 21

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom

May 02

Harrow's Drug Iheezo Is Off To A Great Start

Feb 19

Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity

Jan 30

Harrow sells non‑ophthalmic compounding business, terms undisclosed

Oct 05

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

Sep 27

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Aug 19

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Aug 11
These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

May 23

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

May 12
Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Dec 15
Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Aug 24
Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Mark Baum's remuneration changed compared to Harrow's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$34m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$15mUS$680k

-US$24m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$609k

-US$14m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$21m

Dec 31 2021US$7mUS$565k

-US$18m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

US$10m

Dec 31 2020US$2mUS$570k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$1mUS$489k

US$168k

Sep 30 2019n/an/a

US$16m

Jun 30 2019n/an/a

US$25m

Mar 31 2019n/an/a

US$29m

Dec 31 2018US$1mUS$411k

US$15m

Sep 30 2018n/an/a

-US$6m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$10m

Dec 31 2017US$913kUS$417k

-US$12m

Compensation vs Market: Mark's total compensation ($USD15.26M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Baum (52 yo)

12.7yrs

Tenure

US$15,256,463

Compensation

Mr. Mark L. Baum, J.D., Co-founded Harrow Health, Inc. (formerly, Imprimis Pharmaceuticals, Inc.) and has been Chief Executive Officer since April 1, 2012 and serves as Chairman of the Board since August 1...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Baum
CEO & Chairman of the Board12.7yrsUS$15.26m6%
$ 73.6m
Andrew Boll
CFO & Corporate Secretary9.8yrsUS$7.13m1.6%
$ 19.6m
John Saharek
Chief Commercial Officer2.3yrsUS$5.82m0.84%
$ 10.3m
Dennis Saadeh
Chief Scientific Officer1.9yrsno datano data
Jamie Webb
Director of Communications & Investor Relationsno datano datano data
Brett Burrell
Vice President of Legal & Compliance1.2yrsno datano data
Kim Barratt
Chief Talent Officer`no datano datano data
Mark Mannebach
Head of Regulatory Affairs & Pharmacovigilance1.8yrsno datano data
Greg DiPasquale
Senior VP & Head of Commercialless than a yearno datano data

1.9yrs

Average Tenure

52yo

Average Age

Experienced Management: HROW's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mark Baum
CEO & Chairman of the Board13yrsUS$15.26m6%
$ 73.6m
Adrienne Graves
Independent Directorless than a yearno datano data
Lauren Silvernail
Independent Directorless than a yearno datano data
Perry Sternberg
Lead Independent Director2.8yrsUS$202.50k0%
$ 0
Martin Makary
Independent Director2.8yrsUS$205.00k0.13%
$ 1.5m

2.8yrs

Average Tenure

55yo

Average Age

Experienced Board: HROW's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 00:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Harrow, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Chase KnickerbockerCraig-Hallum Capital Group LLC
Matthew HewittCraig-Hallum Capital Group LLC